Gritstone bio Inc
NASDAQ:GRTS

Watchlist Manager
Gritstone bio Inc Logo
Gritstone bio Inc
NASDAQ:GRTS
Watchlist
Price: 0.0193 USD Market Closed
Market Cap: $2.3m

Net Margin

-910.2%
Current
Improving
by 29.8%
vs 3-y average of -940%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-910.2%
=
Net Income
$-133m
/
Revenue
$14.6m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-910.2%
=
Net Income
$-133m
/
Revenue
$14.6m

Peer Comparison

Country Company Market Cap Net
Margin
US
Gritstone bio Inc
NASDAQ:GRTS
2.3m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 93% of companies in the United States of America
Percentile
7th
Based on 15 072 companies
7th percentile
-910.2%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Gritstone bio Inc
Glance View

Market Cap
2.3m USD
Industry
Biotechnology

Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company is headquartered in Emeryville, California and currently employs 193 full-time employees. The company went IPO on 2018-09-28. The firm discover, develop, manufacture and deliver next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The firm has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate that are collaborating on with Gilead Sciences, Inc. The Company’s product candidates include GRT-C907 (ChAd)/R908 (samRNA), GRT- C909 (ChAd)/R910 (samRNA), GRT-C909 (ChAd)/R910 (samRNA), GRT-R914 (samRNA), GRT-R912 (samRNA) and GRT-R918 (samRNA).

GRTS Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-910.2%
=
Net Income
$-133m
/
Revenue
$14.6m
What is Gritstone bio Inc's current Net Margin?

The current Net Margin for Gritstone bio Inc is -910.2%, which is above its 3-year median of -940%.

How has Net Margin changed over time?

Over the last 3 years, Gritstone bio Inc’s Net Margin has decreased from -157.2% to -910.2%. During this period, it reached a low of -1 358.4% on Sep 30, 2023 and a high of -155.7% on Dec 31, 2021.

Back to Top